menu

Hiding in Plain Sight: A Multidisciplinary Effort to Improve Identification and Treatment of Thyroid Eye Disease

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Hiding in Plain Sight: A Multidisciplinary Effort to Improve Identification and Treatment of Thyroid Eye Disease

1.50 credits
90 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Thyroid eye disease (TED) is the most common noninfectious, autoimmune disease that leads to inflammation and enlargement of the orbital and retro-orbital muscles and connective and fat tissues.

    Drs. Kossler, Murdock, and Bloomgarden discuss how to recognize the signs and symptoms of this complex disease and effective comanagement strategies to improve outcomes for patients with TED.

  • Disclosure of Conflicts of Interest

    It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

    The following faculty/staff members have the following financial relationships with ineligible companies.

    Jennifer Murdock, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alastin Skincare, Galderma Laboratories, L.P., and Horizon Therapeutics. Speaker's Bureau: Horizon Therapeutics.

    Andrea Kossler, MD, FACS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Acelyrin, Argenx, Genentech, Horizon Therapeutics, Immunovant, and Kriya Therapeutics. Grant/Research Support: Horizon Therapeutics, Kriya Therapeutics, Sling, and Viridian.

    Eve Bloomgarden, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Horizon Therapeutics.

    The Evolve staff, planners, and reviewer have no financial relationships with ineligible companies.

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Recognize the prevalence and risk factors for TED
    • Describe the clinical signs and symptoms, grading system, and tests/imaging used to diagnose TED
    • Review the differential diagnosis for TED
    • Evaluate clinical and real-world data investigating the use of biologics in patients with TED
    • Implement educational practices that improve patient knowledge of TED diagnosis, management, and treatment
    • Develop effective comanagement strategies to improve outcomes for patients with TED
  • Target Audience

    This certified continuing education activity is designed for primary care providers, endocrinologists, comprehensive ophthalmologists, optometrists, oculoplastic surgeons, or neuro‐ophthalmologists involved in the care of patients with thyroid eye disease (TED).

  • Accreditation and Credit Designation Statements

    Provided by Evolve Medical Education 

    Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    Evolve designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)


    Evolve Medical Education LLC (Evolve) is a leader in cultivating health care for patients by educating clinical competence of the health care team. Evolve achieves this by developing and distributing high-quality, evidence-based, valid, independent CME/CE activities in a variety of learning formats. These activities are designed to increase clinician’s knowledge, skills, competence and professional performance as well as to promote professional growth, maintenance of licensure, and support quality change in care of patients

  • Commercial Support

    This activity is supported by an unrestricted educational grant from Horizon Therapeutics.

  • Disclaimer

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Horizon Therapeutics.

    This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use. 

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Thyroid eye disease (TED) is the most common noninfectious, autoimmune disease that leads to inflammation and enlargement of the orbital and retro-orbital muscles and connective and fat tissues.

    Drs. Kossler, Murdock, and Bloomgarden discuss how to recognize the signs and symptoms of this complex disease and effective comanagement strategies to improve outcomes for patients with TED.

  • Disclosure of Conflicts of Interest

    It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

    The following faculty/staff members have the following financial relationships with ineligible companies.

    Jennifer Murdock, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alastin Skincare, Galderma Laboratories, L.P., and Horizon Therapeutics. Speaker's Bureau: Horizon Therapeutics.

    Andrea Kossler, MD, FACS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Acelyrin, Argenx, Genentech, Horizon Therapeutics, Immunovant, and Kriya Therapeutics. Grant/Research Support: Horizon Therapeutics, Kriya Therapeutics, Sling, and Viridian.

    Eve Bloomgarden, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Horizon Therapeutics.

    The Evolve staff, planners, and reviewer have no financial relationships with ineligible companies.

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Recognize the prevalence and risk factors for TED
    • Describe the clinical signs and symptoms, grading system, and tests/imaging used to diagnose TED
    • Review the differential diagnosis for TED
    • Evaluate clinical and real-world data investigating the use of biologics in patients with TED
    • Implement educational practices that improve patient knowledge of TED diagnosis, management, and treatment
    • Develop effective comanagement strategies to improve outcomes for patients with TED
  • Target Audience

    This certified continuing education activity is designed for primary care providers, endocrinologists, comprehensive ophthalmologists, optometrists, oculoplastic surgeons, or neuro‐ophthalmologists involved in the care of patients with thyroid eye disease (TED).

  • Accreditation and Credit Designation Statements

    Provided by Evolve Medical Education 

    Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    Evolve designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)


    Evolve Medical Education LLC (Evolve) is a leader in cultivating health care for patients by educating clinical competence of the health care team. Evolve achieves this by developing and distributing high-quality, evidence-based, valid, independent CME/CE activities in a variety of learning formats. These activities are designed to increase clinician’s knowledge, skills, competence and professional performance as well as to promote professional growth, maintenance of licensure, and support quality change in care of patients

  • Commercial Support

    This activity is supported by an unrestricted educational grant from Horizon Therapeutics.

  • Disclaimer

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Horizon Therapeutics.

    This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use. 

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule28 Feb 2024